Asset Details
Do you wish to reserve the book?
Relation of Statin Use Prior to Admission to Severity and Recovery Among COVID-19 Inpatients
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Relation of Statin Use Prior to Admission to Severity and Recovery Among COVID-19 Inpatients
Do you wish to request the book?
Relation of Statin Use Prior to Admission to Severity and Recovery Among COVID-19 Inpatients
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Relation of Statin Use Prior to Admission to Severity and Recovery Among COVID-19 Inpatients
2020
Overview
The impact of statins, angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers (ARBs) on coronavirus disease 2019 (COVID-19) severity and recovery is important given their high prevalence of use among individuals at risk for severe COVID-19. We studied the association between use of statin/angiotensin-converting enzyme inhibitors/ARB in the month before hospital admission, with risk of severe outcome, and with time to severe outcome or disease recovery, among patients hospitalized for COVID-19. We performed a retrospective single-center study of all patients hospitalized at University of California San Diego Health between February 10, 2020 and June 17, 2020 (n = 170 hospitalized for COVID-19, n = 5,281 COVID-negative controls). Logistic regression and competing risks analyses were used to investigate progression to severe disease (death or intensive care unit admission), and time to discharge without severe disease. Severe disease occurred in 53% of COVID-positive inpatients. Median time from hospitalization to severe disease was 2 days; median time to recovery was 7 days. Statin use prior to admission was associated with reduced risk of severe COVID-19 (adjusted OR 0.29, 95%CI 0.11 to 0.71, p < 0.01) and faster time to recovery among those without severe disease (adjusted HR for recovery 2.69, 95%CI 1.36 to 5.33, p < 0.01). The association between statin use and severe disease was smaller in the COVID-negative cohort (p for interaction = 0.07). There was potential evidence of faster time to recovery with ARB use (adjusted HR 1.92, 95%CI 0.81 to 4.56). In conclusion, statin use during the 30 days prior to admission for COVID-19 was associated with a lower risk of developing severe COVID-19, and a faster time to recovery among patients without severe disease.
Publisher
Elsevier Inc,Elsevier Limited,The Author(s). Published by Elsevier Inc
Subject
/ Aged
/ Angiotensin Receptor Antagonists - therapeutic use
/ Angiotensin-converting enzyme inhibitors
/ Angiotensin-Converting Enzyme Inhibitors - therapeutic use
/ Coronavirus Infections - diagnosis
/ Coronavirus Infections - epidemiology
/ Coronavirus Infections - therapy
/ COVID-19
/ Diabetes
/ Enzymes
/ Female
/ Humans
/ Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
/ Male
/ Obesity
/ Patients
/ Pneumonia, Viral - diagnosis
/ Pneumonia, Viral - epidemiology
/ Recovery
/ Severe acute respiratory syndrome coronavirus 2
/ Statins
